# Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

> **NCT05467891** · PHASE2 · RECRUITING · sponsor: **Oana Danciu** · enrollment: 200 (estimated)

## Conditions studied

- Locoregional Recurrence
- Hormone Receptor-positive Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Fulvestrant
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT05467891
- **Lead sponsor:** Oana Danciu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2028-08-15
- **Final completion:** 2029-08-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467891, "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05467891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*